INDIANAPOLIS--(BUSINESS WIRE)--Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced that it is presenting preclinical data from its Heat Shock Protein 90 (Hsp90) inhibitor SNX-5422 program, showing promising anti-tumor effects both alone and in combination with checkpoint inhibitors, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
“Results from these two studies reaffirm our belief in the potential of SNX-5422 both as a monotherapy and in combination with immuno-oncology drugs,” said Everardus (Eric) Orlemans, Ph.D, Chief Scientific Officer and Senior Vice President, Development, Esanex. “We are conducting further research to explore the potential of SNX-5422 in other indications as well as through our ongoing Phase 1b trial in chronic lymphocytic leukemia. The results from the combination research support further development of SNX-5422 in combination with checkpoint inhibitors for the potential treatment of a number of cancer types.”
The two posters will be presented October 29th at 12:30 – 4:00 pm EST, in Hall E, Pennsylvania Convention Center.
Poster B139:
“Promising antitumor effects of SNX-5422 in combination with
checkpoint inhibitors in an MC38 murine model”, presented at the
session PO.B20 – Therapeutic Agents: Other Topics.
SNX-5422 is an
orally active prodrug of SNX-2112, a potent, highly selective inhibitor
of Hsp90. The results described in the poster show that SNX-5422 at
either 25 mg/kg or 40 mg/kg, in combination with the immune checkpoint
inhibitors anti-PD1, PD-L1 or CTLA4, demonstrated significant antitumor
activity in the MC38 murine colon cancer model.
Poster B026:
“SNX-2112 interferes with mitochondrial metabolism in TP53 mutant
tumors”, presented at the session PO.B05 – Metabolism.
In vitro
work with SNX-2112, the active derivative of SNX-5422, demonstrated
significant antitumor activity in TP53 null tumors and in rearranged MYC
hematologic and selected solid tumors (e.g., hepatocellular carcinoma,
mesothelioma). This activity appears to be, in part, the result of
interference with cancer related metabolic pathways.
About SNX-5422
SNX-5422 is a chemically unique, orally
active Hsp90 inhibitor that has provided durable clinical responses in
open label trials in non-small cell lung cancer (NSCLC) and
neuroendocrine tumors (NET). The potential of SNX-5422 in hematologic
cancers is currently being explored in a chronic lymphocytic leukemia
(CLL) open label clinical trial (clinicaltrials.gov ID#NCT02973399).
With approximately 200 patients treated to date, SNX-5422 has a
well-established safety profile that supports studying it in combination
with existing approved drugs in a variety of clinical settings.
About Esanex
Esanex is a clinical-stage company with new
insights into Heat Shock Proteins as an important cancer target. Our
lead program, SNX-5422, has shown durable clinical responses in
rationally-designed combination studies in patients with non-small cell
lung cancer and neuroendocrine tumors. We are also advancing SNX-5422 in
select hematological tumors, including CLL. www.esanexpharma.com
